Functional involvement of superior temporal sulcus in quality of life of patients with schizophrenia

Psychiatry Research - Neuroimaging

Volumn 202, Issue 2, 2012, Pages 155-160

  Boyer, Laurent ^a   Richieri, Raphaelle ^a,b   Faget, Catherine ^a,b   Padovani, Romain ^a,b   Vaillant, Florence ^b   Mundler, Olivier ^a,c   Lançon, Christophe ^a,b   Auquier, Pascal ^a   Guedj, Eric ^a,c,d  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL SAINTE MARGUERITE   (France)

^c Aix Marseille University   (France)

^d AIX MARSEILLE UNIVERSITY   (France)

Author keywords

23 Single photon emission computed tomography (SPECT); Metacognition; Quality of life; Schizophrenia; Theory of mind

Indexed keywords

ETHYLCYSTEINATE DIMER TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRAIN REGION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; NEUROIMAGING; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; SCHIZOPHRENIA; SELF ESTEEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUPERIOR TEMPORAL SULCUS;

ADULT; BRAIN MAPPING; CYSTEINE; FEMALE; FUNCTIONAL LATERALITY; HUMANS; MALE; ORGANOTECHNETIUM COMPOUNDS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TEMPORAL LOBE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; YOUNG ADULT;

EID: 84863878897     PISSN: 09254927     EISSN: 18727506     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2012.02.006     Document Type: Article

References (44)

1. Aghababian V., Auquier P., Baumstarck-Barrau K., Lancon C. Relationship between insight and self-reported quality of life among shizophrenic patients. L'Encéphale 2011, 37:162-171.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, text revision. APA, Washington, DC. 4th ed.
3. Andreasen N.C., Calarge C., A.O'Leary D.S. Theory of mind and schizophrenia: a positron emission tomography study of medication-free patients. Schizophrenia Bulletin 2008, 34:708-719.
4. Appelberg B., Tuisku K., Joffe G. Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine. European Psychiatry 2004, 19:516-518.
5. Auquier P., Simeoni M.C., Sapin C., Reine G., Aghababian V., Cramer J., Lancon C. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophrenia Research 2003, 63:137-149.
6. Awad A.G., Voruganti L.N. Intervention research in psychosis: issues related to the assessment of quality of life. Schizophrenia Bulletin 2000, 26:557-564.
7. Awad A.G., Voruganti L.N., Heslegrave R.J. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Quality of Life Research 1997, 6:21-26.
8. Bora E., Yucel M., Pantelis C. Theory of mind impairment in schizophrenia: meta-analysis. Schizophrenia Research 2009, 109:1-9.
9. Boyer L., Simeoni M.C., Loundou A., D'Amato T., Reine G., Lancon C., Auquier P. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophrenia Research 2010, 121:241-250.
10. Boyer L., Aghababian V., Richieri R., Loundou A., Padovani R., Simeoni M.C., Auquier P., Lancon C. Insight into illness, neurocognition and quality of life in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2012, 36:271-276.
11. Calman K.C. Quality of life in cancer patients--a hypothesis. Journal of Medical Ethics 1984, 10:124-127.
12. Cohen C.I., Hassamal S.K., Begum N. General coping strategies and their impact on quality of life in older adults with schizophrenia. Schizophrenia Research 2011, 127:223-228.
13. Corcoran R., Mercer G., Frith C.D. Schizophrenia, symptomatology and social inference: investigating "theory of mind" in people with schizophrenia. Schizophrenia Research 1995, 17:5-13.
14. Eack S.M., Newhill C.E. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophrenia Bulletin 2007, 33:1225-1237.
15. Ertugrul A., Volkan-Salanci B., Basar K., Karli Oguz K., Demir B., Ergun E.L., Senturk S., Erbas B., Cila A., Ulug B. The effect of clozapine on regional cerebral blood flow and brain metabolite ratios in schizophrenia: relationship with treatment response. Psychiatry Research: Neuroimaging 2009, 174:121-129.
16. Frith C.D., Corcoran R. Exploring 'theory of mind' in people with schizophrenia. Psychological Medicine 1996, 26:521-530.
17. Frith U., Frith C.D. Development and neurophysiology of mentalizing. Philosophical Transactions of the Royal Society of London 2003, 358:459-473.
18. Gallagher H.L., Frith C.D. Functional imaging of 'theory of mind'. Trends in Cognitive Sciences 2003, 7:77-83.
19. Guedj E., Barbeau E.J., Didic M., Felician O., de Laforte C., Ceccaldi M., Mundler O., Poncet M. Identification of subgroups in amnestic mild cognitive impairment. Neurology 2006, 67:356-358.
20. Higuchi Y., Sumiyoshi T., Kawasaki Y., Matsui M., Arai H., Kurachi M. Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300. Schizophrenia Research 2008, 101:320-330.
21. Hofer A., Baumgartner S., Bodner T., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., Fleischhacker W.W. Patient outcomes in schizophrenia. II. The impact of cognition. European Psychiatry 2005, 20:395-402.
22. Hofer A., Baumgartner S., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., Schweigkofler H., Schwitzer J., Fleischhacker W.W. Patient outcomes in schizophrenia. I. Correlates with sociodemographic variables, psychopathology, and side effects. European Psychiatry 2005, 20:386-394.
23. Hoffmeyer-Zlotnik J.H.P., Wolfn C. Advances in cross-national comparison. A European Working Book for Demographic and SocioEconomic Variables 2003, Kluwer 431 Academic/Plenum Publishers, New York. J.H.P. Hoffmeyer-Zlotnik, C. Wolfn (Eds.).
24. Kay S.R., Opler L.A., Fiszbein A. Significance of positive and negative syndromes in chronic schizophrenia. The British Journal of Psychiatry 1986, 149:439-448.
25. Kurtz M.M., Tolman A. Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: what is their relationship?. Schizophrenia Research 2011, 127(1-3):157-162.
26. Kurtz M.M., Wexler B.E., Fujimoto M., Shagan D.S., Seltzer J.C. Symptoms versus neurocognition as predictors of change in life skills in schizophrenia after outpatient rehabilitation. Schizophrenia Research 2008, 102:303-311.
27. Lançon C., Auquier P., Nayt G., Reine G. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophrenia Research 2000, 42:231-239.
28. Leplege A., Hunt S. The problem of quality of life in medicine. JAMA: The Journal of the American Medical Association 1997, 278:47-50.
29. Materna S., Dicke P.W., Thier P. The posterior superior temporal sulcus is involved in social communication not specific for the eyes. Neuropsychologia 2008, 46:2759-2765.
30. Mauri M.C., Gaietta M., Dragogna F., Valli I., Cerveri G., Marotta G. Hallucinatory disorder, an original clinical picture? Clinical and imaging data. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32:523-530.
31. Moritz S., Veckenstedt R., Randjbar S., Vitzthum F., Woodward T.S. Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms. Psychological Medicine 2011, 1-10.
32. Murphy E.R., Brent B.K., Benton M., Pruitt P., Diwadkar V., Rajarethinam R.P., Keshavan M.S. Differential processing of metacognitive evaluation and the neural circuitry of the self and others in schizophrenia: a pilot study. Schizophrenia Research 2011, 116:252-258.
33. Quee P.J., van der Meer L., Bruggeman R., de Haan L., Krabbendam L., Cahn W., Mulder N.C., Wiersma D., Aleman A. Insight in psychosis: Relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophrenia Bulletin 2011, 37:29-37.
34. Richieri R., Boyer L., Farisse J., Colavolpe C., Mundler O., Lancon C., Guedj E. Predictive value of brain perfusion SPECT for rTMS response in pharmacoresistant depression. European Journal of Nuclear Medicine and Molecular Imaging 2011, 38:1715-1722.
35. Ritsner M. The Distress/Protection Vulnerability Model of Quality of Life Impairment Syndrome 2007, 3-20. Springer, Dordrecht, Netherland. M. Ritsner, A.G. Awad (Eds.).
36. Sibitz I., Unger A., Woppmann A., Zidek T., Amering M. Stigma resistance in patients with schizophrenia. Schizophrenia Bulletin 2011, 37:316-323.
37. Staring A.B., Van der Gaag M., Van den Berge M., Duivenvoorden H.J., Mulder C.L. Stigma moderates the associations of insight with depressed mood, low self-esteem, and low quality of life in patients with schizophrenia spectrum disorders. Schizophrenia Research 2009, 115:363-369.
38. Sumiyoshi T., Higuchi Y., Itoh T., Matsui M., Arai H., Suzuki M., Kurachi M., Sumiyoshi C., Kawasaki Y. Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sLoreta. Psychiatry Research: Neuroimaging 2009, 172:180-183.
39. Tolman A.W., Kurtz M.M. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophrenia Bulletin 2012, 38(2):304-315.
40. van Zelst C. Stigmatization as an environmental risk in schizophrenia: a user perspective. Schizophrenia Bulletin 2009, 35:293-296.
41. Voruganti L.N., Awad A.G. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study. Schizophrenia Research 2006, 88:179-186.
42. Wood S., William J.I. Reintegration to normal living as a proxy to quality of life. Journal of Chronic Diseases 1987, 40:497-499.
43. Wykes T., Huddy V., Cellard C., McGurk S.R., Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. The American Journal of Psychiatry 2011, 168:472-485.
44. Zissi A., Barry M.M., Cochrane R. A mediational model of quality of life for individuals with severe mental health problems. Psychological Medicine 1998, 28:1221-1230.